

Public Health 4<sup>th</sup> Floor; 300 Carlton Street Winnipeg MB R3B 3M9 vaccines@gov.mb.ca

June 22, 2023

## Re: COVID-19 Janssen (JCOVDEN™) Vaccine Discontinuation in Canada Effective June 30, 2023

Dear Health Care Provider:

The Janssen JCOVDEN™ COVID-19 vaccine will no longer be distributed or authorized for use in Canada effective June 30, 2023. Janssen initiated this discontinuation and will no longer be marketing the JCOVDEN™ vaccine in Canada or offering surveillance or regulatory updates beyond June 30, 2023. This is not a result of health or safety concerns with the JCOVDEN™ vaccine.

Based on this business decision by Janssen, the Public Health Agency of Canada (PHAC) is working with all jurisdictions to have all available supply of the Janssen (JCOVDEN™) vaccine returned to PHAC for disposal by June 30, 2023. Health Canada will also be withdrawing the Drug Identification Number (DIN) by June 30, 2023.

If a client requests a non-mRNA vaccine, they may be offered Novavax. Manitoba Health is aware that current inventory of Novavax vaccine is expiring on June 30, 2023 and is working closely with PHAC to explore further supply for Manitoba.

Please check your inventory for any JCOVDEN™ vaccine stock and return to the provincial distribution warehouse (MDA) as soon as possible. Given that all returned doses will be processed for disposal, routine cold-chain monitoring will not be necessary.

manitoba.ca/health/publichealth/cdc/div/docs/vbrpp.pdf

Provincial resources are being updated to reflect the discontinuation of this vaccine and will be available shortly. Resources for Health Care Providers can be found at: <a href="mailtoba.ca/covid19/health-care-providers.html">manitoba.ca/covid19/health-care-providers.html</a>

Updated provincial factsheets will be available in the coming days at: https://www.manitoba.ca/covid19/public-resources.html

Please share this information with all relevant colleagues in your facility/clinic.

Sincerely,

"Original Signed By"

"Original Signed By"

Richard Baydack, PhD
A/Co – Executive Director
Population and Public Health
Communicable Disease Control

Natalie Casaclang, MD, CCFP, FRCPC Medical Officer of Health, Population and Public Health